Judith Dunn - 19 Jan 2022 Form 4 Insider Report for Fulcrum Therapeutics, Inc. (FULC)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	FULC	Stock Option (right to buy)	Award	$0	+140,890		$0.000000	140,890	19 Jan 2022	Common Stock	140,890	$12.69	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	This option was granted on January 19, 2022 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2022, subject to continued service.

President, Research & Development